Jump to main content
Jump to site search

Issue 4, 2012
Previous Article Next Article

Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate

Author affiliations

Abstract

Nanoparticle (NP)-based targeted drug delivery involves cell-specific targeting followed by a subsequent therapeutic action from the therapeutic carried by the NP system. NPs conjugated with methotrexate (MTX), a potent inhibitor of dihydrofolate reductase (DHFR) localized in cytosol, have been under investigation as a delivery system to target cancer cells to enhance the therapeutic index of methotrexate, which is otherwise non-selectively cytotoxic. Despite improved therapeutic activity from MTX-conjugated NPs in vitro and in vivo, the therapeutic action of these conjugates following cellular entry is poorly understood; in particular it is unclear whether the therapeutic activity requires release of the MTX. This study investigates whether MTX must be released from a nanoparticle in order to achieve the therapeutic activity. We report herein light-controlled release of methotrexate from a dendrimer-based conjugate and provide evidence suggesting that MTX still attached to the nanoconjugate system is fully able to inhibit the activity of its enzyme target and the growth of cancer cells.

Graphical abstract: Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 24 Oct 2011, accepted on 01 Dec 2011 and first published on 11 Jan 2012


Article type: Paper
DOI: 10.1039/C2PP05355A
Citation: Photochem. Photobiol. Sci., 2012,11, 653-660
  •   Request permissions

    Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate

    S. K. Choi, T. P. Thomas, M. Li, A. Desai, A. Kotlyar and J. R. Baker, Photochem. Photobiol. Sci., 2012, 11, 653
    DOI: 10.1039/C2PP05355A

Search articles by author